TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8381674

Group type: EXPERIMENTAL
Intervention: 7 g/day of a 85% n-3 fatty acid concentrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no n-3 fatty acids)
Number of subjects: 14
Study: 3690030

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (1.5 mg.kg-1, orally twice a day for 14 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 13
Study: 30849287

Group type: EXPERIMENTAL
Intervention: Individual therapy for 6 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Group therapy for 6 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Group therapy
Number of subjects: 41
Study: 31099218

Group type: EXPERIMENTAL
Intervention: Combined therapy (abdominal acupuncture + periodic therapy of Chinese herbal medicine)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 84

Group type: COMPARATOR
Intervention: Western medication (clomiphene citrate + human chorionic gonadotrophin)
Number of subjects: 84
Study: 28893106

Group type: EXPERIMENTAL
Intervention: 22-gauge biopsy needles (PC22)
Number of subjects: 103

Group type: COMPARATOR
Intervention: 25-gauge biopsy needles (PC25)
Number of subjects: 103
Study: 25444222

Group type: EXPERIMENTAL
Intervention: Community consultation and public disclosure (CC/PD) process using multimedia approach
Number of subjects: 643000

Group type: EXPERIMENTAL
Intervention: Cost of the CC/PD process
Number of subjects: 643000

Group type: EXPERIMENTAL
Intervention: Effectiveness of the CC/PD process
Number of subjects: 643000
Study: 23577719

Group type: EXPERIMENTAL
Intervention: Boiled barley kernels (BK)
Number of subjects: 19

Group type: COMPARATOR
Intervention: White wheat bread (WWB)
Number of subjects: 19
Study: 22010914

Group type: EXPERIMENTAL
Intervention: Earlier ART (within 2 weeks after the initiation of treatment for tuberculosis)
Number of subjects: 809

Group type: COMPARATOR
Intervention: Later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Earlier ART (for patients with CD4+ T-cell counts of less than 50 per cubic millimeter)
Number of subjects: 809

Group type: COMPARATOR
Intervention: Later ART (for patients with CD4+ T-cell counts of less than 50 per cubic millimeter)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Earlier ART
Number of subjects: 809

Group type: COMPARATOR
Intervention: Later ART
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 809
Study: 19332440

Group type: EXPERIMENTAL
Intervention: Culturally sensitive, seven-minute video intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational pamphlet
Number of subjects: 0
Study: 17317365

Group type: EXPERIMENTAL
Intervention: Left bundle branch block (BBB) at randomization
Number of subjects: 5477

Group type: EXPERIMENTAL
Intervention: Right bundle branch block (BBB) at randomization
Number of subjects: 5477

Group type: EXPERIMENTAL
Intervention: Left bundle branch block (BBB) during follow-up
Number of subjects: 5477

Group type: EXPERIMENTAL
Intervention: Right bundle branch block (BBB) during follow-up
Number of subjects: 5477
Study: 15080862

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 0
Study: 12584692

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg via 15-minute infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9652613

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (excluding participants with colds)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo (excluding participants with colds)
Number of subjects: 262
Study: 7645530

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg 3 times daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propranolol (40 mg 3 times daily)
Number of subjects: 100
Study: 2111669

Group type: EXPERIMENTAL
Intervention: Intravenous Flecainide acetate (1.5 mg/kg over 5 minutes) - Group I
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous Flecainide acetate (2 mg/kg over 5 minutes) - Group II
Number of subjects: 19
Study: 359778

Group type: EXPERIMENTAL
Intervention: Intramuscular oxycodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular codeine
Number of subjects: 0
Study: 31232275

Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) 62.5 µg once-daily added to fluticasone furoate/vilanterol (FF/VI) 200/25 µg once-daily
Number of subjects: 17
Study: 27885712

Group type: EXPERIMENTAL
Intervention: Lactulose plus albumin (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lactulose alone (group B)
Number of subjects: 120
Study: 25536197

Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 45
Study: 23415571

Group type: EXPERIMENTAL
Intervention: Rhinoplasty
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (Septoplasty)
Number of subjects: 110
Study: 21684715

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of autologous tissue repair cells (TRCs)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 86
Study: 18332170

Group type: EXPERIMENTAL
Intervention: Amoxicillin sprinkle (475 mg for ages 6 months to 4 years, 775 mg for ages 5 to 12 years) QD for 7 days
Number of subjects: 579

Group type: COMPARATOR
Intervention: Penicillin VK (10 mg/kg QID for 10 days, max 250 mg QID)
Number of subjects: 579
Study: 16823726

Group type: EXPERIMENTAL
Intervention: Vildagliptin (25 mg, bid)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 15013052

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (phenytoin)
Number of subjects: 0
Study: 10994155

Group type: EXPERIMENTAL
Intervention: Trimebutine tablets (100 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: New tablet formulation (Eurogalena, 100 mg)
Number of subjects: 24
Study: 9116532

Group type: EXPERIMENTAL
Intervention: Anticipated discharge order forms
Number of subjects: 103

Group type: COMPARATOR
Intervention: No anticipated discharge order forms (Control)
Number of subjects: 103
Study: 8466376

Group type: EXPERIMENTAL
Intervention: Indwelling Teflon catheter for heparin administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Twice-daily subcutaneous injections of heparin
Number of subjects: 12
Study: 3725999

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 29921651

Group type: EXPERIMENTAL
Intervention: AlloCSC‐01
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 27336413

Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS for 10 min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS for 20 min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS for 10 min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS for 20 min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All conditions of anodal tDCS
Number of subjects: 20
Study: 24781223

Group type: EXPERIMENTAL
Intervention: Respiratory training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG-BFB-therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23803696

Group type: EXPERIMENTAL
Intervention: rs2838732 (ITGB2) T allele
Number of subjects: 1841

Group type: EXPERIMENTAL
Intervention: rs2838732 (ITGB2) T allele among never smokers
Number of subjects: 1841

Group type: EXPERIMENTAL
Intervention: rs2838732 (ITGB2) T allele among former smokers
Number of subjects: 1841

Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 1841
Study: 22032072

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 40
Study: 18454658

Group type: EXPERIMENTAL
Intervention: PRP + DFDBA
Number of subjects: 60

Group type: COMPARATOR
Intervention: DFDBA + saline
Number of subjects: 60
Study: 16585078

Group type: EXPERIMENTAL
Intervention: Cylinder oxygen
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cylinder air
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study: 14748998

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) plus cyclophosphamide (CPA) intermittent intravenous pulse therapy (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) plus prednisone and tripterygium wilfordii hook f (T(whf)) (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prednisone alone (Group C)
Number of subjects: 30
Study: 10744208

Group type: EXPERIMENTAL
Intervention: Injection speed of 20 seconds (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Injection speed of 60 seconds (group B)
Number of subjects: 70
Study: 8938306

Group type: EXPERIMENTAL
Intervention: Postoperative intervertebral disk enhancement
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Linear enhancement within the intervertebral disk
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: End‐plate enhancement
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Clinical symptoms association with disk enhancement
Number of subjects: 94
Study: 1543382

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3304518

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) with postoperative levamisole
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Supportive treatment only (Control)
Number of subjects: 141
Study: 29697830

Group type: EXPERIMENTAL
Intervention: Metformin with or without rosiglitazone, metformin plus lifestyle
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Irregular menses group
Number of subjects: 190

Group type: COMPARATOR
Intervention: Regular menses group
Number of subjects: 190
Study: 26792390

Group type: EXPERIMENTAL
Intervention: Brief communication intervention (prompts) to aid solicitation of additional concerns (ACs)
Number of subjects: 18
Study: 24490648

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Implementation intentions formed
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Self-affirmation with implementation intentions formed
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control (no self-affirmation)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Implementation intentions not formed
Number of subjects: 332
Study: 22615787

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (bilateral BL2, GB14, TE 23, Ex1, ST1, GB20, LI4, LI11 and single GV23)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Artificial tears (sodium carboxymethylcellulose)
Number of subjects: 150
Study: 20839418

Group type: EXPERIMENTAL
Intervention: Topical steroids (mometasone furoate) applied twice daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intralesional steroids (triamcinolone acetonide) injected at monthly intervals (1 to 2 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical steroids (mometasone furoate)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intralesional steroids (triamcinolone acetonide)
Number of subjects: 45
Study: 18257978

Group type: EXPERIMENTAL
Intervention: Indiplon 10 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Indiplon 20 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Indiplon 5 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Zopiclone 3.75 mg
Number of subjects: 2
Study: 16925111

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating proteins (ESPs)
Number of subjects: 0
Study: 12962794

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) with Mycophenolate Mofetil (MMF)
Number of subjects: 65
Study: 10362169

Group type: EXPERIMENTAL
Intervention: Active management of labor
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Early epidural placement
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control
Number of subjects: 255
Study: 7579848

Group type: EXPERIMENTAL
Intervention: Warm (37 degrees C)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tepid (32 degrees C)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cold (20 degrees C)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 51
Study: 2288825

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg p.o.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg p.o.
Number of subjects: 22
Study: 6250699

Group type: EXPERIMENTAL
Intervention: Nabilone (2 mg every 12 hours)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Prochlorperazine (10 mg every 12 hours)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nabilone and Prochlorperazine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 37
Study: 31397827

Group type: EXPERIMENTAL
Intervention: Electronic version of the Children's Hospital of Pittsburgh Pediatric Logistic Organ Dysfunction‐2 score
Number of subjects: 21335

Group type: EXPERIMENTAL
Intervention: Electronic version of the Children's Hospital of Pittsburgh Pediatric Risk of Mortality‐IV
Number of subjects: 21335

Group type: EXPERIMENTAL
Intervention: All models
Number of subjects: 21335
Study: 28408814

Group type: EXPERIMENTAL
Intervention: Intelligent volume-assured pressure support (IVAPS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pressure-controlled (spontaneous timed [ST]) non-invasive ventilation
Number of subjects: 14
Study: 26487343

Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF)
Number of subjects: 4747

Group type: EXPERIMENTAL
Intervention: TDF/emtricitabine (FTC)
Number of subjects: 4747

Group type: EXPERIMENTAL
Intervention: TDF
Number of subjects: 4747

Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 4747
Study: 23599623

Group type: EXPERIMENTAL
Intervention: Combination of normal saline and hydroxyethyl starch (HES) (SH group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of normal saline, hydroxyethyl starch and glutamine (SHG group)
Number of subjects: 120
Study: 21566420

Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate
Number of subjects: 0
Study: 19289857

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 533

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 533
Study: 16415689

Group type: EXPERIMENTAL
Intervention: Restasis (0.05% cyclosporine) + Systane
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Systane
Number of subjects: 61

Group type: COMPARATOR
Intervention: Restasis (0.05% cyclosporine) + Refresh
Number of subjects: 61

Group type: COMPARATOR
Intervention: Systane alone
Number of subjects: 61
Study: 15470281

Group type: EXPERIMENTAL
Intervention: IUCD users
Number of subjects: 100

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 100
Study: 11419611

Group type: EXPERIMENTAL
Intervention: Relaxation Response Meditation (twice a day for 15 minutes for six weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Relaxation Response Meditation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Wait List Control (symptom monitoring for six weeks)
Number of subjects: 16
Study: 9257207

Group type: EXPERIMENTAL
Intervention: Propofol (50 to 200 micrograms/kg/min)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Isoflurane (0.5 to 1.3% end‐tidal)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Propofol (50 to 200 micrograms/kg/min) in women
Number of subjects: 118

Group type: COMPARATOR
Intervention: Isoflurane (0.5 to 1.3% end‐tidal) in women
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Propofol (50 to 200 micrograms/kg/min) in men
Number of subjects: 118

Group type: COMPARATOR
Intervention: Isoflurane (0.5 to 1.3% end‐tidal) in men
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Propofol for maintenance of anesthesia
Number of subjects: 118

Group type: COMPARATOR
Intervention: Isoflurane for maintenance of anesthesia
Number of subjects: 118
Study: 8275619

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pentobarbital 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pentobarbital 240 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3435105

Group type: EXPERIMENTAL
Intervention: Liquid detergent containing 4% CHG
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Liquid detergent containing 2% CHG
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Foam containing 4% CHG
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonantiseptic soap (control)
Number of subjects: 50
Study: 28956449

Group type: EXPERIMENTAL
Intervention: Dorzolamide loaded‐nanoliposome
Number of subjects: 20

Group type: COMPARATOR
Intervention: Marketed dorzolamide HCl eye drop
Number of subjects: 20
Study: 27004531

Group type: EXPERIMENTAL
Intervention: Carbetocin 100 mcg as a slow intravenous bolus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Carbetocin 100 mcg as a short-infusion in 100 ml 0.9% sodium chloride
Number of subjects: 100
Study: 25339342

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 42
Study: 23511711

Group type: EXPERIMENTAL
Intervention: Midazolam (0.0001‐3 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ketoconazole (400 mg q.d.)
Number of subjects: 12
Study: 20107296

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS) 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS) > 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS) 50-100 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS)
Number of subjects: 0
Study: 18387161

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 15
Study: 16246442

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g) administration
Number of subjects: 21

Group type: COMPARATOR
Intervention: No ascorbic acid administration (control)
Number of subjects: 21
Study: 12687332

Group type: EXPERIMENTAL
Intervention: 600 mg gemfibrozil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole (first dose 200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: gemfibrozil and itraconazole combination
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: gemfibrozil alone and in combination with itraconazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 10588314

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg once daily
Number of subjects: 922

Group type: COMPARATOR
Intervention: Valacyclovir 500 mg twice daily
Number of subjects: 922
Study: 8678177

Group type: EXPERIMENTAL
Intervention: Day hospital/crisis respite program
Number of subjects: 197

Group type: COMPARATOR
Intervention: Inpatient hospitalization
Number of subjects: 197
Study: 1656713

Group type: EXPERIMENTAL
Intervention: ARI treatment (sorbinil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6356855

Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31857319

Group type: EXPERIMENTAL
Intervention: Biomarker (AR-V7) guided clinical treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional standard management (no biomarker guidance)
Number of subjects: 70
Study: 30240342

Group type: EXPERIMENTAL
Intervention: Consent and data-sharing scenarios (3 different scenarios)
Number of subjects: 5737
Study: 27120420

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Health Anxiety (CBT-HA)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 444
Study: 25417405

Group type: EXPERIMENTAL
Intervention: Xinmailong injection
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 102
Study: 22458917

Group type: EXPERIMENTAL
Intervention: DDS‐06C (75 mg tramadol/650 mg paracetamol)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 20492026

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Programme (6-week duration)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 317
Study: 18628467

Group type: EXPERIMENTAL
Intervention: Poxvirus-based PSA vaccine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nilutamide
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Vaccine followed by Nilutamide
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nilutamide followed by Vaccine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Vaccine arm (Gleason score <7)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Vaccine arm (PSA <20 ng/dL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Vaccine arm (prior radiation therapy)
Number of subjects: 42
Study: 15959537

Group type: EXPERIMENTAL
Intervention: AM(ex) (0600-0800 h; 30 min at 50% VO(2peak))
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PM(ex) (1700-1900 h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: AM(ex) and PM(ex)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control days (not specified)
Number of subjects: 14